zoster vaccine live + influenza vaccine

The concomitant administration of **Zostavax** (zoster vaccine live) and a seasonal **influenza vaccine** refers to a clinical immunization regimen studied to ensure the safety and immunogenicity of both vaccines when given during the same healthcare visit. Zostavax, developed by Merck & Co., is a live attenuated vaccine containing the Oka/Merck strain of the varicella-zoster virus (VZV), designed to prevent herpes zoster (shingles) and postherpetic neuralgia in adults aged 50 and older. Seasonal influenza vaccines are typically inactivated (split-virion or subunit) or live attenuated preparations containing antigens from circulating Influenza A and B strains. Clinical trials demonstrated that co-administration at separate injection sites does not result in significant immune interference, maintaining protective antibody titers for both VZV and influenza. While Zostavax has been largely replaced by the recombinant zoster vaccine (Shingrix) in many markets, its co-administration with influenza vaccines was a standard clinical practice for over a decade.

Other names

zoster vaccine liveshingles vaccineflu vaccineinfluenza vaccinezoster vaccine live (Oka/Merck) + influenza vaccine